Advertisement
Canada markets open in 3 hours 5 minutes

  • S&P/TSX

    21,823.22
    +94.67 (+0.44%)
     

  • S&P 500

    5,064.20
    +45.81 (+0.91%)
     

  • DOW

    38,225.66
    +322.37 (+0.85%)
     

  • CAD/USD

    0.7318
    +0.0004 (+0.06%)
     

  • CRUDE OIL

    79.17
    +0.22 (+0.28%)
     

  • Bitcoin CAD

    81,081.64
    +2,197.04 (+2.79%)
     

  • CMC Crypto 200

    1,285.78
    +8.80 (+0.69%)
     

  • GOLD FUTURES

    2,308.50
    -1.10 (-0.05%)
     

  • RUSSELL 2000

    2,016.11
    +35.88 (+1.81%)
     

  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     

  • NASDAQ futures

    17,769.00
    +119.25 (+0.68%)
     

  • VOLATILITY

    14.41
    -0.27 (-1.84%)
     

  • FTSE

    8,208.55
    +36.40 (+0.45%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6809
    -0.0008 (-0.12%)
     

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

Sensei Biotherapeutics
·2 min read
Sensei Biotherapeutics
Sensei Biotherapeutics

BOSTON, April 09, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘KRAS and VISTA - Better Approaches for Key Targets’ at Canaccord Genuity’s Horizons in Oncology Virtual Conference on Monday, April 15th at 2:00 p.m. ET.

The panel will feature Dr. Shiraj Sen, M.D., Ph.D., Medical Oncologist and Director of Clinical Research at NEXT Oncology-Dallas. Dr. Sen is an investigator on the ongoing Phase 1/2 clinical trial for SNS-101.

About Sensei Biotherapeutics 
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

ADVERTISEMENT

Investor Contact: 
Michael Biega 
Senior Director, Investor Relations
Sensei Biotherapeutics 
mbiega@senseibio.com

Media Contact: 
Joyce Allaire 
LifeSci Advisors 
Jallaire@lifesciadvisors.com